CRISPR/Cas9 system is one of the most common used gene-editing tools, which was first described as an immune defense system. Considering its easy-to-use, simple-to-design and multiplexed engineering, CRISPR/Cas9 is widely used for genome engineering in microbes, mammalian cells/models and plants.

$BIEL The NO PAIN ACT is now LAW

$BIEL BioElectronics Corp. Episode 12 The Pitch
Wow! Home based pain treatment. FDA cleared

$BIEL DonJoy® EME Knee Wrap listed as Best Seller on the DonJoy® Performance website

https://www.donjoyperformance.com/

https://www.donjoyperformance.com/eme-knee-wrap

Powered by ActiPatch®

$BIEL sells in all these countries!

$BIEL Heating Up as ActiPatch® and RecoveryRx® Gain Traction & Co Looks to Expand into New Markets

$BIEL UCSD Postoperative Pain Trial

CONFIRMATION OF BIT225 EFFECTIVENESS AGAINST
COVID-19 IN ANIMALS ( BITRF : PKC )
https://www.asx.com.au/asxpdf/20220317/pdf/4573pqrhd0c5kp.pdf?

What do you think about IMMUNOVANT (IMVT)?

BIEL has 1000% growth in 6 months.

Biotech on solid fundamentals. It is way undervalued.

It will revolutionize how the world treats pain. KT Tape and DonJoy (billion dollar company) have recently partnered with BIEL and are stocking Walmart, CVS, Walgreens as we speak for a massive international role out. BIEL has many sources of revenue making them a very safe investment. This will be the next Tesla and Amazon of stocks if they aren’t bought out before that happens.

BIEL

Seeking Alpha article.

Is PKTX The Next ORMP?

Oct. 23, 2017 5:24 PM

ProtoKinetix, Incorporated, PKTX is a small molecular biotechnology company based in West Virginia that has been announcing major progress recently, and has some investors thinking that its’ starting to look like an early-stage version of another biopharma platform technology company that is making major waves in treating diabetes, Oramed Pharmaceuticals Inc., ORMP.

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) is a clinical-stage pharmaceutical company based in Israel that has developed a unique proprietary platform technology that allows for the oral delivery of drugs presently administered only via injection.  The Company has a $143M market cap as of October 21st, 2017, and its stock is up 76% since this February. 

Most of the attributed reason for the stock surge stems from the successful conclusion of their Phase IIb trial of its oral insulin capsule ORMD-0801 in the treatment of type 2 diabetes, and the anticipation of the beginning of its Phase III trials.

In September 2017, ORMD announced that it successfully concluded its meeting with the U.S. Food and Drug Administration (FDA), getting clear guidance that the regulatory pathway for submission of ORMD-0801 would be a Biologics License Application (BLA). 

ProtoKinetix, Incorporated (OTC:OTCQB:PKTX) is a much smaller company with a $16M market cap, but like ORMD, it too is a platform technology company with many potential applications.  The company is actively developing their patented family of hyper stable, potent glycopeptides (AAGP™) that enhance the engraftment and protection of transplanted cells used in regenerative medicine.   

Amongst the various indications PKTX is researching are Kidney Ischemia, Normothermic Liver Perfusion, Retinal Cell Replacement, and Monoclonal Antibody Production.  However, like ORMD, they are further along in clinical trials investigating its ability to help treat Type 1 Diabetes.  The Company is currently in Phase II of a first-in-human clinical trial being conducted by a well-respected team at the University of Alberta that started in March 2017.  Much of what will drive the PKTX story going forward is the success of this trial.

Besides the strong science behind the PKTX story, it is heartening to see that the company has done an excellent job of balance sheet management.  There is no debt on the books, and for a biotech company, it has a remarkably small burn of only $1M in SG&A on a yearly basis.

At some point, soon I see PKTX as a prime takeover candidate.  Likely won’t happen until trial results begin to come out, which I would expect to see sometime in early in 2018.  Novo Nordisk, (NYSE:NVO) and Eli Lilly, (NYSE:LLY) are both active in the Type 1 diabetes space and would be on the list of companies interested in acquiring them.

It should also be noted that the CEO has funded a significant amount of the development himself, and owns 24% of the Company, and is only paying himself a salary of $1.  That is unheard of among small-cap biotechs.  Most of often a management team owns very little stock and pays themselves exorbitant salaries.  It’s nice to see a management team be “all-in” like the folks at PKTX.   With no debt and an extremely small burn, there is very little downside to the stock at this point.   At these levels, it is a great place to accumulate and hold until we begin to see the data from the trials.

Disclosure: I am/we are long ORMP, PKTX.

PhaseRx Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
03.27.17

SEATTLE, March 27, 2017 /PRNewswire/ -- PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today reported financial results for the fourth quarter and full year ended December 31, 2016 and provided an update on its corporate activities.

"PhaseRx continued to make progress during the fourth quarter of 2016 through the announcement of positive results from our non-human primate safety study, and with our lead development candidate, PRX-OTC, receiving orphan drug designation by the FDA," said Robert W. Overell, Ph.D., president and chief executive officer. "In 2017, we anticipate completing our GLP toxicology and GMP manufacturing activities and submitting an IND for PRX-OTC in the fourth quarter. I look forward to updating investors on our progress with PRX-OTC and other programs as the year unfolds."

Full Year 2016 and Subsequent Highlights

On February 8, 2017, PhaseRx announced a poster presentation for its lead product candidate, PRX-OTC, at the 13th Annual WORLDSymposium™ 2017 that took place February 13-17, 2017. PRX-OTC is in development for the treatment of Ornithine Transcarbamylase Deficiency (OTCD).
On November 28, 2016, the company announced that its lead candidate, PRX-OTC, which is being developed for the treatment of OTCD, received orphan drug designation by the U.S. Food and Drug Administration (FDA).
On November 8, 2016, PhaseRx announced positive results from the company's single escalating dose response study in non-human primates. The administration of mRNA delivered using the company's proprietary Hybrid mRNA TechnologyTM platform in a large animal model was safe and well tolerated at all dose levels tested.
On October 25, 2016, the company presented data evaluating its mRNA Hybrid Technology platform at the 4th International mRNA Health Conference in Boston. The poster, titled, 'Targeted mRNA delivery to the liver for Intracellular Enyzme Replacement Therapy (i-ERT)' was presented by Pierrot Harvie, Ph.D., Associate Director of Formulations at PhaseRx.
On July 11, 2016, PhaseRx announced the presentation of data evaluating its mRNA Hybrid TechnologyTM platform at the 43rd Annual Meeting & Exposition of the Controlled Release Society (CRS) that took place July 17-20, 2016, in Seattle. The presentation was titled "Targeted mRNA Delivery to the Liver for Intracellular Enzyme Replacement Therapy (i-ERT)."
On June 21, 2016, the company announced product pipeline advancements including the selection of its lead product candidate, PRX-OTC, for treatment of OTCD, and positive proof-of-concept data for a second product candidate, PRX-ASL, for treatment of Argininosuccinate Lyase Deficiency (ASLD).
On June 7, 2016, PhaseRx entered into a loan and security agreement with Hercules Capital, Inc., pursuant to which it received $6 million.
On May 23, 2016, the company closed its initial public offering of 3,700,000 shares of common stock at a price of $5.00 per share for aggregate gross proceeds of $18.5 million.

Financial Results for the Three Months and Year Ended December 31, 2016

Total operating expenses for the fourth quarter of 2016 were $3.3 million, compared to $1.7 million of operating expenses in 2015. Total operating expenses for the year ended December 31, 2016 were $18.3 million compared to $6.2 million for 2015. The increase in operating expenses in the fourth quarter of 2016 was primarily due to increased research and development costs to execute PhaseRx's product development plan of its lead drug candidate PRX-OTC, increased costs associated with being a publicly-traded company and an increase in non-cash stock-based compensation expenses. The operating expenses for the year ended December 31, 2016 included non-recurring, non-cash financial advising fees of $7.5 million related to the company's IPO.

The net loss for the quarter ended December 31, 2016 was $3.5 million, or $0.30 per share, compared to a net loss of $2.3 million, or $4.25 per share, for the quarter ended December 31, 2015. The net loss for the year ended December 31, 2016 was $20.1 million, or $2.68 per share, compared to $7.4 million, or $14.22 per share for 2015.

As of December 31, 2016, the company had cash, cash equivalents, and marketable securities of $15.5 million. The company believes it has sufficient cash to fund its operations for at least the next 12 months.

About PhaseRx

PhaseRx is a biopharmaceutical company dedicated to developing mRNA products for the treatment of children with inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy (i-ERT). PhaseRx's initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of twelve and are characterized by the body's inability to remove ammonia from the blood with potentially devastating consequences for patients. The company's i-ERT approach is enabled by its proprietary Hybrid mRNA Technology™ platform. PhaseRx is headquartered in Seattle. For more information, please visit www.phaserx.com.

Safe Harbor Statement

This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the fact that the company has incurred significant losses since its inception and anticipates that it will continue to incur significant losses for the foreseeable future, (ii) the company being dependent on technologies it has licensed and that it may need to license in the future, (iii) the fact that the company will need to raise substantial additional funding to develop its planned products, (iv) the fact that the company's Hybrid mRNA Technology has not previously been tested beyond company preclinical studies, and that mRNA-based drug development is unproven, (v) the fact that all of the company's programs are in preclinical studies or early stage research and it is uncertain that any company product candidates will receive regulatory approval or be commercialized, (vi) the fact that development of the company's product candidates will be expensive, time-consuming and subject to regulatory approval, (vii) the company expecting to continue to incur significant research and development expenses, (viii) the company becoming dependent on collaborative arrangements for the development and commercialization of its products, (ix) the company's ability to adequately protect its proprietary technology from legal challenges, infringement or alternative technologies and (x) the biotechnology and pharmaceutical industries being intensely competitive. More detailed information about the company and the risk factors that may affect the realization of forward looking statements is set forth in the company's filings with the Securities and Exchange Commission (SEC), including the most recent annual report on Form 10-K and its quarterly reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Contacts:
Company Contact:
Erin Cox
PhaseRx, Inc.
Director of Investor Relations
erin@phaserx.com
206.805.6306

Corporate Communications Contact:
Jason Spark
Canale Communications
Senior Vice President
jason@canalecomm.com
619.849.6005

[http://www.imarcgroup.com/biotechnology-industry/] [Recombinant Proteins Market]

The global biotechnology market is expected to grow at a CAGR of 7% during 2013-2017 reaching sales worth nearly US$ 166 billion by 2017. This market, however, is expected to undergo a number of transformations which would impact the course of its growth. These transitions include a shift of growth from the developed to the emerging markets, an increasing focus on monoclonal antibodies compared to therapeutic proteins and an increasing penetration of biosimilars/follow-on-biologics compared to their branded versions. As a result of these transformations, the need for a user friendly, robust and comprehensive biotechnology market intelligence has become imperative for investors, researchers, consultants, marketing strategists, and all those who are planning to foray into the biotechnology market in some form or the other.

To know more about this report, please visit: www.imarcgroup.com/biotechnology-industry/